ORKA · NASDAQ · STOCK
Oruka Therapeutics, Inc.
$104.56
52W $13.06 – $107.55
59/100
$6.31B
-43.8
-0.39
Is ORKA Bullish or Bearish?
Mixed.
Innellis AI committee rates Oruka Therapeutics, Inc. (ORKA) Watch with a composite score of 59/100
, based on 5 analysts with 60% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +0.54 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -19.46 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- ROE of only -26.0% -- cheap may mean cheap for a reason — Value
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 86 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 23.4% signals elevated volatility — Risk
- News sentiment is negative (-0.25 across 4 articles, 14d) — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
59/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 53%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -26.0% -- cheap may mean cheap for a reason
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 74 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 23.4% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
49
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.25 across 4 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
74.0
Overbought
MACD Histogram
0.569
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.97
Inside Bands
Price vs Moving Averages
EMA 9
$99.23
Above
EMA 21
$94.57
Above
EMA 50
$85.46
Above
EMA 200
$57.48
Above
Fundamental Analysis
Valuation
67
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-43.8×
P/B Ratio
11.87×
PEG Ratio
-0.54
Dividend Yield
0.00%
52W High
$107.55
52W Low
$13.06
Quality & Growth
ROE
-2234.1%
ROA
-2157.8%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -43.8 (inexpensive relative to a 15-40x range); Price-to-book of 11.9x; PEG ratio of -0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -22.3%; Return on assets of -21.6%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 23.76 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-1.65); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full ORKA Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →